News coverage about Celgene (NASDAQ:CELG) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene earned a news impact score of 0.04 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.2821271200315 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Risankizumab Could Be AbbVie’s Long-Term Growth Driver (finance.yahoo.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action … (globenewswire.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG (finance.yahoo.com)
- Valuing Stocks Using Ratios and Multiples: Celgene Corporation (NASDAQ:CELG), PPL Corporation (NYSE:PPL … (journalfinance.net)
- Celgene (CELG) PT Set at $134.00 by Mizuho (americanbankingnews.com)
A number of research firms have weighed in on CELG. Mizuho reissued a “buy” rating and issued a $128.00 target price on shares of Celgene in a report on Sunday, February 4th. Credit Suisse Group set a $125.00 price target on Celgene and gave the stock a “buy” rating in a research report on Monday, January 8th. Cann restated a “buy” rating and issued a $163.00 price target on shares of Celgene in a research report on Thursday, February 15th. Goldman Sachs reduced their price target on Celgene from $97.00 to $85.00 and set a “sell” rating for the company in a research report on Monday, March 26th. Finally, Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target for the company. in a research report on Monday, December 18th. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Celgene presently has a consensus rating of “Hold” and a consensus target price of $126.95.
Shares of NASDAQ:CELG traded up $0.88 during trading on Tuesday, hitting $91.42. The company had a trading volume of 2,567,489 shares, compared to its average volume of 7,781,640. The firm has a market capitalization of $67,244.50, a price-to-earnings ratio of 13.36, a PEG ratio of 0.60 and a beta of 1.48. Celgene has a one year low of $84.25 and a one year high of $147.17. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. During the same period last year, the company earned $1.61 EPS. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. analysts expect that Celgene will post 7.66 earnings per share for the current fiscal year.
Celgene announced that its Board of Directors has initiated a share buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.
In other Celgene news, Director Ernest Mario sold 13,370 shares of Celgene stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $94.49, for a total transaction of $1,263,331.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark J. Alles bought 3,260 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares in the company, valued at $16,441,277.60. The disclosure for this purchase can be found here. Insiders have sold a total of 41,120 shares of company stock valued at $3,879,509 over the last three months. 0.95% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-celgene-celg-stock-price.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.